Anelixis Therapeutics was formed in 2013 as a for-profit subsidiary of ALS Therapy Development
Institute (ALS TDI, www.als.net), a nonprofit biotechnology
organization dedicated to developing effective treatments for ALS. Every member of the Anelixis
Therapeutics team is committed to advancing treatments that will have a meaningful impact on
the lives of patients by helping them battle back their disease progression.
Anelixis Therapeutics is a clinical stage development company located in Cambridge, Massachusetts
with a portfolio focused on immune modulatory drugs for neurodegenerative diseases with a focus
on amyotrophic lateral sclerosis (ALS) and Alzheimer’s Disease (AD).
Anelixis Therapeutics is developing monoclonal antibodies that block a specific immune system
target expressed on lymphocytes (CD40LG) known to drive neurodegeneration. By way of exclusive
licensing arrangements with ALS TDI, Anelixis has the right to the development of methods to treat
ALS by administering an antibody that blocks the interaction of CD40 and CD40LG, among other
targets. Patents held under license by Anelixis have been issued or are pending in the US, Hong
Kong, Japan and Europe. For a preview of current patent status, click
Anelixis Therapeutics’ lead candidate, developed on the basis of these patents is AT-1501. AT-1501
has showed success in reducing the activation of specific aspects of the immune system, which in turn
slows the progression of disease. The process by which AT-1501 accomplishes this exciting outcome is
Anelixis Therapeutics has assembled an expert
clinical advisory team and consulting team. The company
has developed a cell line and manufacturing process to develop AT-1501. The team has completed
IND-enabling toxicology studies in non-human primates and intends to file an IND for first in human
studies in early 2018.
To support the further development of AT-1501 toward clinical trial, Anelixis Therapeutics has been
awarded philanthropic grant support from several of the most well-known and respected funders of ALS
research, including the ALS Association, the ALS Finding a Cure Foundation and ALS ONE.
For more information about Anelixis Therapeutics investment opportunities,